Imbria Pharmaceuticals

Executive Summary

Imbria Pharmaceuticals is a private, Phase 2-stage biopharmaceutical company headquartered in Cambridge, MA, focused on developing novel small-molecule therapies that target cardiac energy metabolism. Founded in 2018, the company leverages a deep understanding of how heart cells produce and utilize energy to create treatments for cardiovascular diseases with limited therapeutic options. By enhancing or restoring the cell's ability to generate and use energy, Imbria aims to transform care for patients suffering from conditions such as heart failure, where current treatments often fail to address the underlying metabolic dysfunction. Their approach represents a paradigm shift from traditional hemodynamic-focused therapies to energy-based interventions. The company is advancing its lead candidate through Phase 2 clinical trials, positioning itself at a critical juncture where proof-of-concept data could significantly de-risk the program. If successful, Imbria's therapies could address a large unmet need in cardiovascular medicine, potentially improving outcomes for millions of patients. As a private entity, Imbria relies on strategic partnerships and private financing to progress its pipeline. The upcoming period is crucial as the company prepares to report clinical results and seek additional funding or collaborations to advance its promising metabolic platform.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 clinical data readout for lead candidate50% success
• Q2 2026Potential partnership or licensing deal for cardiac metabolic platform40% success
• H1 2026Series C or later-stage financing round70% success